https://www.selleckchem.com/pr....oducts/talabostat.ht
ents and patient preference. PROSPERO CRD42017058161. PROSPERO CRD42017058161. This scoping review aims to identify and systematically map the available evidence concerning the prognostic biomarkers for malignant transformation of oral potentially malignant disorders (OPMDs), and to identify and analyze possible knowledge gaps in this field of literature. It is hypothesized that diagnosis and treatment of oral cancer in its early stages may be the key to improving the prognosis and reducing treatment-related consequences. Oral potent
Like
Comment
Share
